TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Predictive Value of AMH (AMH=Anti Müllerian Hormone ) in IVF (IVF=In Vitro Fertilization ); a Prospective Randomized Controlled Trial
Brief Summary: The primary aim of this trial is to compare two groups of women undergoing IVF (IVF=in vitro fertilisation ) treatment, to investigate if assessment of AMH (AMH=Anti-Müllerian hormone ), in addition to assessment of maternal age, AFC (AFC=antral follicle count ) and BMI (BMI=body mass index ) gives a more optimal COH (COH=controlled ovarian stimulation than does assessment of only age, AFC and BMI, measured as number of patients obtaining 5-12 oocytes during COH.


Options:
A: Arm Label: AMH-group; Type: EXPERIMENTAL; Interventions: Other: AMH-analysis | Arm Label: Non-AMH-group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: AMH-analysis; Assigned to Arm(s): AMH-group
B: Arm Label: Highly Purified Menotrophin; Type: EXPERIMENTAL; Interventions: Drug: Highly purified menotrophin | Arm Label: Recombinant FSH; Type: ACTIVE_COMPARATOR; Interventions: Drug: Recombinant FSH | Intervention Type: DRUG; Name: Highly purified menotrophin; Assigned to Arm(s): Highly Purified Menotrophin | Intervention Type: DRUG; Name: Recombinant FSH; Assigned to Arm(s): Recombinant FSH
C: Arm Label: 5.2 µg; Type: EXPERIMENTAL; Interventions: Drug: FE 999049 | Arm Label: 6.9 µg; Type: EXPERIMENTAL; Interventions: Drug: FE 999049 | Arm Label: 8.6 µg; Type: EXPERIMENTAL; Interventions: Drug: FE 999049 | Arm Label: 10.3 µg; Type: EXPERIMENTAL; Interventions: Drug: FE 999049 | Arm Label: 12.1 µg; Type: EXPERIMENTAL; Interventions: Drug: FE 999049 | Arm Label: 11 µg FbM (150 IU); Type: ACTIVE_COMPARATOR; Interventions: Drug: Gonal - F | Intervention Type: DRUG; Name: FE 999049; Assigned to Arm(s): 10.3 µg, 12.1 µg, 5.2 µg, 6.9 µg, 8.6 µg | Intervention Type: DRUG; Name: Gonal - F; Assigned to Arm(s): 11 µg FbM (150 IU)
D: Arm Label: 450 IU daily dose of gonadotrophin; Type: ACTIVE_COMPARATOR; Interventions: Drug: menotropins for injection, Drug: urofollitropin for injection | Arm Label: 600 IU daily dose of gonadotrophin; Type: EXPERIMENTAL; Interventions: Drug: menotropins for injection, Drug: urofollitropin for injection | Intervention Type: DRUG; Name: menotropins for injection; Assigned to Arm(s): 450 IU daily dose of gonadotrophin, 600 IU daily dose of gonadotrophin | Intervention Type: DRUG; Name: urofollitropin for injection; Assigned to Arm(s): 450 IU daily dose of gonadotrophin, 600 IU daily dose of gonadotrophin

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Prospective, Randomized, Double-blind, Phase II Study to Evaluate the Safety and Efficacy of Topical Thrombin (Human) Grifols as an Adjunct to Hemostasis During Vascular, Hepatic, Soft Tissue, and Spinal Open Surgeries
Brief Summary: This purpose of this clinical trial was to study the safety and efficacy of Topical Thrombin (Human) Grifols as an add-on treatment to help stop bleeding during vascular, liver, soft tissue, and spinal surgical procedures.


Options:
A: Arm Label: Tranexamic Acid (TXA); Type: ACTIVE_COMPARATOR; Interventions: Drug: Tranexamic Acid | Arm Label: Placebo (0.9% normal saline); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (Saline) | Arm Label: Hypotension-avoidance strategy; Type: ACTIVE_COMPARATOR; Interventions: Other: Perioperative hypotension-avoidance strategy | Arm Label: Perioperative hypertension-avoidance strategy; Type: PLACEBO_COMPARATOR; Interventions: Other: Perioperative hypertension-avoidance strategy | Intervention Type: DRUG; Name: Tranexamic Acid; Assigned to Arm(s): Tranexamic Acid (TXA) | Intervention Type: DRUG; Name: Placebo (Saline); Assigned to Arm(s): Placebo (0.9% normal saline) | Intervention Type: OTHER; Name: Perioperative hypotension-avoidance strategy; Assigned to Arm(s): Hypotension-avoidance strategy | Intervention Type: OTHER; Name: Perioperative hypertension-avoidance strategy; Assigned to Arm(s): Perioperative hypertension-avoidance strategy
B: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Metoprolol controlled release (CR) | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Metoprolol controlled release (CR); Assigned to Arm(s): A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): B
C: Arm Label: Fibrocaps + Gelatin Sponge; Type: EXPERIMENTAL; Interventions: Biological: Fibrocaps, Biological: Gelatin sponge | Arm Label: Gelatin Sponge; Type: ACTIVE_COMPARATOR; Interventions: Biological: Gelatin sponge | Intervention Type: BIOLOGICAL; Name: Fibrocaps; Assigned to Arm(s): Fibrocaps + Gelatin Sponge | Intervention Type: BIOLOGICAL; Name: Gelatin sponge; Assigned to Arm(s): Fibrocaps + Gelatin Sponge, Gelatin Sponge
D: Arm Label: IG1202-A (Vascular); Type: EXPERIMENTAL; Interventions: Biological: Human thrombin, Biological: Bovine thrombin | Arm Label: IG1202-B (Hepatic); Type: EXPERIMENTAL; Interventions: Biological: Human thrombin, Biological: Bovine thrombin | Arm Label: IG1202-C (Soft Tissue); Type: EXPERIMENTAL; Interventions: Biological: Human thrombin, Biological: Bovine thrombin | Arm Label: IG1202-D (Spinal); Type: EXPERIMENTAL; Interventions: Biological: Human thrombin, Biological: Bovine thrombin | Intervention Type: BIOLOGICAL; Name: Human thrombin; Assigned to Arm(s): IG1202-A (Vascular), IG1202-B (Hepatic), IG1202-C (Soft Tissue), IG1202-D (Spinal) | Intervention Type: BIOLOGICAL; Name: Bovine thrombin; Assigned to Arm(s): IG1202-A (Vascular), IG1202-B (Hepatic), IG1202-C (Soft Tissue), IG1202-D (Spinal)

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Impact of a Program to Prevent the Risk of Antisocial Behavior and Attacks of Patients or Attendant on Healthcare Workers in an Ophthalmic Emergency Unit.
Brief Summary: At the hospital, the attacks against health professionals are becoming commonplace, making working conditions difficult. The ophthalmological emergencies are a perfect testing ground to evaluate the effectiveness of a series of original actions to prevent the occurrence of violence against healthcare workers. The main objective is to measure the impact of an integrated prevention of the occurrence of antisocial behavior or attacks against the healthcare workers.

The prevention program combines five interventions (steps): 1) a computer sorting algorithm and specific screens for calling patients in waiting rooms, 2) a clear signage to direct patients between waiting rooms, treatment rooms and administrative et medical offices, 3) Posts information on the activity of emergency services displayed on screens, in the waiting rooms, 4) a mediator/go-between/conciliator, 5) and a dummy surveillance camera.

This is an interrupted time series study. All patients admitted to the ophthalmological emergency unit of a university hospital located in Lyon, France, are included in the study, from June 2013 to Sept 2015


Options:
A: Arm Label: Trichuris Suis Ova (TSO); Type: EXPERIMENTAL; Interventions: Drug: Trichuris Suis Ova | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Trichuris Suis Ova | Intervention Type: DRUG; Name: Trichuris Suis Ova; Assigned to Arm(s): Placebo, Trichuris Suis Ova (TSO)
B: Intervention Type: DRUG; Name: fluoxetine; Assigned to Arm(s): N/A
C: Arm Label: All patients admitted to the ophthalmologic emergency unit.; Type: N/A; Interventions: N/A
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: N-acetylcysteine | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: N-acetylcysteine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Intensive Versus Standard Follow up to Improve Continuous Positive Airway Pressure Compliance: The Greek Experience
Brief Summary: The purpose of this study was to compare the effects on sleepiness, quality of life, depression, hospitalization and deaths rate, of intensive vs standard interventions, on CPAP adherence, 2 years after CPAP initiation.


Options:
A: Arm Label: Conservative Medical Therapy (CMT); Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Conservative Medical Therapy (CMT) | Arm Label: Sham PAP (Sham); Type: SHAM_COMPARATOR; Interventions: Behavioral: Conservative Medical Therapy (CMT), Device: Sham PAP (Sham) | Arm Label: Active PAP with RT Support (Active-Beh); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Conservative Medical Therapy (CMT), Device: Active PAP with RT Support (Active-Beh) | Arm Label: Active PAP with Behavioral Modification (Active+Beh); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Conservative Medical Therapy (CMT), Device: Active PAP with Behavioral Modification (Active+Beh) | Intervention Type: BEHAVIORAL; Name: Conservative Medical Therapy (CMT); Assigned to Arm(s): Active PAP with Behavioral Modification (Active+Beh), Active PAP with RT Support (Active-Beh), Conservative Medical Therapy (CMT), Sham PAP (Sham) | Intervention Type: DEVICE; Name: Sham PAP (Sham); Assigned to Arm(s): Sham PAP (Sham) | Intervention Type: DEVICE; Name: Active PAP with RT Support (Active-Beh); Assigned to Arm(s): Active PAP with RT Support (Active-Beh) | Intervention Type: DEVICE; Name: Active PAP with Behavioral Modification (Active+Beh); Assigned to Arm(s): Active PAP with Behavioral Modification (Active+Beh)
B: Arm Label: OSA CPAP; Type: ACTIVE_COMPARATOR; Interventions: Drug: Eszopiclone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo control | Intervention Type: DRUG; Name: Eszopiclone; Assigned to Arm(s): OSA CPAP | Intervention Type: DRUG; Name: Placebo control; Assigned to Arm(s): Placebo
C: Arm Label: Standard Care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard care | Arm Label: Intensive care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Intensive care | Intervention Type: BEHAVIORAL; Name: Standard care; Assigned to Arm(s): Standard Care | Intervention Type: BEHAVIORAL; Name: Intensive care; Assigned to Arm(s): Intensive care
D: Arm Label: Auto Aflex; Type: ACTIVE_COMPARATOR; Interventions: Device: Auto AFlex | Arm Label: Auto CPAP; Type: ACTIVE_COMPARATOR; Interventions: Device: Auto CPAP | Arm Label: CPAP; Type: ACTIVE_COMPARATOR; Interventions: Device: CPAP | Intervention Type: DEVICE; Name: Auto AFlex; Assigned to Arm(s): Auto Aflex | Intervention Type: DEVICE; Name: Auto CPAP; Assigned to Arm(s): Auto CPAP | Intervention Type: DEVICE; Name: CPAP; Assigned to Arm(s): CPAP

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Controlled, Single-blind Study of Effects of Pectin on Flora Intestinal Colonization and Maintenance After Fecal Transplantation to Patients With Inflammatory Bowel Disease
Brief Summary: The purpose of this study is to evaluate the effect and safety of pectin and fecal microbiota transplantation on patients with inflammatory bowel disease. The investigators hypothesize that patients who take pectin can promote the migration of probiotics in intestine engraftment, reduce pathogenic agents'adhesion to intestinal mucosa, cut down the inflammation, and to maintain intestinal flora diversity and steady state in a long time.


Options:
A: Arm Label: Study Participants; Type: EXPERIMENTAL; Interventions: Drug: Gut Microbial Transplantation | Intervention Type: DRUG; Name: Gut Microbial Transplantation; Assigned to Arm(s): Study Participants
B: Arm Label: faecal transplantation; donor faeces; Type: ACTIVE_COMPARATOR; Interventions: Other: treatment with faecal transplantation (donor faeces) | Arm Label: faecal transplantation; placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: treatment with faecal transplantation (own faeces) | Intervention Type: OTHER; Name: treatment with faecal transplantation (donor faeces); Assigned to Arm(s): faecal transplantation; donor faeces | Intervention Type: OTHER; Name: treatment with faecal transplantation (own faeces); Assigned to Arm(s): faecal transplantation; placebo
C: Arm Label: co-transplantation of FMT and pectin; Type: EXPERIMENTAL; Interventions: Other: co-transplantation of FMT and pectin | Arm Label: single fecal microbiota transplantation; Type: ACTIVE_COMPARATOR; Interventions: Other: single fecal microbiota transplantation | Arm Label: give pectin 20g/d; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: pure give pectin 20g/d for five days | Intervention Type: OTHER; Name: co-transplantation of FMT and pectin; Assigned to Arm(s): co-transplantation of FMT and pectin | Intervention Type: OTHER; Name: single fecal microbiota transplantation; Assigned to Arm(s): single fecal microbiota transplantation | Intervention Type: DIETARY_SUPPLEMENT; Name: pure give pectin 20g/d for five days; Assigned to Arm(s): give pectin 20g/d
D: Arm Label: Fecal Microbiota Enema; Type: EXPERIMENTAL; Interventions: Biological: Fecal Microbiota Enema | Arm Label: Normal Saline Enema; Type: PLACEBO_COMPARATOR; Interventions: Biological: Normal Saline Enema | Intervention Type: BIOLOGICAL; Name: Fecal Microbiota Enema; Assigned to Arm(s): Fecal Microbiota Enema | Intervention Type: BIOLOGICAL; Name: Normal Saline Enema; Assigned to Arm(s): Normal Saline Enema

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Controlled, Single-blind Study of Effects of Pectin on Flora Intestinal Colonization and Maintenance After Fecal Transplantation to Patients With Inflammatory Bowel Disease
Brief Summary: The purpose of this study is to evaluate the effect and safety of pectin and fecal microbiota transplantation on patients with inflammatory bowel disease. The investigators hypothesize that patients who take pectin can promote the migration of probiotics in intestine engraftment, reduce pathogenic agents'adhesion to intestinal mucosa, cut down the inflammation, and to maintain intestinal flora diversity and steady state in a long time.


Options:
A: Arm Label: colonoscope via of FMT; Type: N/A; Interventions: Device: colonoscope | Arm Label: Transendoscopic enteral tubing; Type: N/A; Interventions: Device: transendoscopic enteral tubing | Intervention Type: DEVICE; Name: transendoscopic enteral tubing; Assigned to Arm(s): Transendoscopic enteral tubing | Intervention Type: DEVICE; Name: colonoscope; Assigned to Arm(s): colonoscope via of FMT
B: Arm Label: co-transplantation of FMT and pectin; Type: EXPERIMENTAL; Interventions: Other: co-transplantation of FMT and pectin | Arm Label: single fecal microbiota transplantation; Type: ACTIVE_COMPARATOR; Interventions: Other: single fecal microbiota transplantation | Arm Label: give pectin 20g/d; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: pure give pectin 20g/d for five days | Intervention Type: OTHER; Name: co-transplantation of FMT and pectin; Assigned to Arm(s): co-transplantation of FMT and pectin | Intervention Type: OTHER; Name: single fecal microbiota transplantation; Assigned to Arm(s): single fecal microbiota transplantation | Intervention Type: DIETARY_SUPPLEMENT; Name: pure give pectin 20g/d for five days; Assigned to Arm(s): give pectin 20g/d
C: Arm Label: SER-109; Type: EXPERIMENTAL; Interventions: Biological: SER-109 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: BIOLOGICAL; Name: SER-109; Assigned to Arm(s): SER-109 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Metronidazole+doxycylcine+terbinafine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Metronidazole, Drug: Doxycycline, Drug: Terbinafine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Metronidazole; Assigned to Arm(s): Metronidazole+doxycylcine+terbinafine | Intervention Type: DRUG; Name: Doxycycline; Assigned to Arm(s): Metronidazole+doxycylcine+terbinafine | Intervention Type: DRUG; Name: Terbinafine; Assigned to Arm(s): Metronidazole+doxycylcine+terbinafine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Does the Harmonic Scalpel Reduce Operating Time and Blood Loss in Patients Undergoing Major Surgery for Oral Cavity Squamous Cell Carcinoma? A Prospective, Randomized Trial.
Brief Summary: The harmonic scalpel is a tool that may reduce operative blood loss. Some studies also indicate it may result in faster surgery. A recently published randomized study from our group shows the harmonic scalpel reduces blood loss in neck dissection but it did not offer any reduction in OR time. The present study investigates the utility of the harmonic scalpel in resections involving removal of oral cavity tissues as well as the neck. Oral cavity resections are especially prone to blood loss and we believe the harmonic scalpel will confer benefits in this type of surgery, potentially reducing the need for blood transfusion.


Options:
A: Arm Label: harmonic scalpel; Type: EXPERIMENTAL; Interventions: Procedure: surgical resection | Arm Label: standard technique; Type: ACTIVE_COMPARATOR; Interventions: Procedure: surgical resection | Intervention Type: PROCEDURE; Name: surgical resection; Assigned to Arm(s): harmonic scalpel, standard technique
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Procedure: Selective neck dissection | Arm Label: 2; Type: OTHER; Interventions: Procedure: Conventional Neck dissection | Intervention Type: PROCEDURE; Name: Selective neck dissection; Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: Conventional Neck dissection; Assigned to Arm(s): 2
C: Arm Label: Wait and Watch; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Therapeutic Neck Dissection | Arm Label: Elective Neck dissection; Type: EXPERIMENTAL; Interventions: Procedure: Elective neck dissection in early oral cancer | Intervention Type: PROCEDURE; Name: Elective neck dissection in early oral cancer; Assigned to Arm(s): Elective Neck dissection | Intervention Type: PROCEDURE; Name: Therapeutic Neck Dissection; Assigned to Arm(s): Wait and Watch
D: Intervention Type: OTHER; Name: questionnaire administration; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: psychosocial assessment and care; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: quality-of-life assessment; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: regional lymph node dissection; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: therapeutic conventional surgery; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Does the Harmonic Scalpel Reduce Operating Time and Blood Loss in Patients Undergoing Major Surgery for Oral Cavity Squamous Cell Carcinoma? A Prospective, Randomized Trial.
Brief Summary: The harmonic scalpel is a tool that may reduce operative blood loss. Some studies also indicate it may result in faster surgery. A recently published randomized study from our group shows the harmonic scalpel reduces blood loss in neck dissection but it did not offer any reduction in OR time. The present study investigates the utility of the harmonic scalpel in resections involving removal of oral cavity tissues as well as the neck. Oral cavity resections are especially prone to blood loss and we believe the harmonic scalpel will confer benefits in this type of surgery, potentially reducing the need for blood transfusion.


Options:
A: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Fluorescence visualization device | Arm Label: B; Type: EXPERIMENTAL; Interventions: Procedure: Fluorescence visualization device | Intervention Type: PROCEDURE; Name: Fluorescence visualization device; Assigned to Arm(s): B | Intervention Type: PROCEDURE; Name: Fluorescence visualization device; Assigned to Arm(s): A
B: Arm Label: harmonic scalpel; Type: EXPERIMENTAL; Interventions: Procedure: surgical resection | Arm Label: standard technique; Type: ACTIVE_COMPARATOR; Interventions: Procedure: surgical resection | Intervention Type: PROCEDURE; Name: surgical resection; Assigned to Arm(s): harmonic scalpel, standard technique
C: Arm Label: Wait and Watch; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Therapeutic Neck Dissection | Arm Label: Elective Neck dissection; Type: EXPERIMENTAL; Interventions: Procedure: Elective neck dissection in early oral cancer | Intervention Type: PROCEDURE; Name: Elective neck dissection in early oral cancer; Assigned to Arm(s): Elective Neck dissection | Intervention Type: PROCEDURE; Name: Therapeutic Neck Dissection; Assigned to Arm(s): Wait and Watch
D: Arm Label: Ligusure assisted neck dissection; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Neck dissection | Arm Label: Conventional neck dissection; Type: OTHER; Interventions: Procedure: Neck dissection | Intervention Type: PROCEDURE; Name: Neck dissection; Assigned to Arm(s): Conventional neck dissection, Ligusure assisted neck dissection

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Adherence to Therapy in COPD Patients Under Dose Escalation of Roflumilast
Brief Summary: Main adverse events of Roflumilast are weight loss, loss of appetite, insomnia, headache, diarrhea, vomiting, and nausea. Although the majority of these adverse reactions were mild or moderate. They occurred mainly at the beginning of therapy and mostly resolved with continued treatment around for two weeks according to experiences of clinicians. These adverse events occur more often in Roflumilast 500 μg than 250 μg, having negative impact on compliance of patients at the early stage of treatments.

Thus, investigators aim to compare the drop-out rates between the usual dosage (Roflumilast 500 μg once daily) and the dose escalation (Roflumilast 250 μg once daily for 4 weeks and then escalating dose of 500 μg once daily).


Options:
A: Arm Label: NMS; Type: EXPERIMENTAL; Interventions: Other: New Medicine Service | Arm Label: Current Practice; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: New Medicine Service; Assigned to Arm(s): NMS
B: Arm Label: Activity Monitoring - Smartphone; Type: N/A; Interventions: N/A | Arm Label: Activity Monitoring - Wearable; Type: N/A; Interventions: N/A
C: Arm Label: Roflumilast escalation dosage; Type: EXPERIMENTAL; Interventions: Drug: Roflumilast escalation dosage | Arm Label: Roflumilast conventional dosage; Type: EXPERIMENTAL; Interventions: Drug: Roflumilast conventional dosage | Intervention Type: DRUG; Name: Roflumilast escalation dosage; Assigned to Arm(s): Roflumilast escalation dosage | Intervention Type: DRUG; Name: Roflumilast conventional dosage; Assigned to Arm(s): Roflumilast conventional dosage
D: Arm Label: Pathway; Type: EXPERIMENTAL; Interventions: Other: COPD evidence based care pathway | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: COPD evidence based care pathway; Assigned to Arm(s): Pathway

Answer: C